Internal Medicine – Page 17

Enhancing Venous Thromboembolism Prevention Through Patient-Centered Nurse and Patient Education in Community Hospitals

By MedXY 10/10/2025

A nurse-driven, patient-centered education bundle significantly reduced missed doses of venous thromboembolism prophylaxis in a community hospital, demonstrating scalable improvements in prophylaxis adherence beyond academic centers.

Gastroenterology Internal Medicine

Simplifying Ulcerative Colitis Treatment: Evaluating a Single 1600 mg 5-ASA Tablet Regimen in the EASI Trial

By MedXY 10/09/2025

The EASI trial compared a once-daily 1600 mg 5-ASA tablet with the conventional three 800 mg tablet regimen for ulcerative colitis, finding similar adherence and relapse rates, suggesting a feasible simpler alternative.

Gastroenterology Internal Medicine news

Persistent High Mortality in Severe Alcohol-Associated Hepatitis: Insights from a Five-Decade Meta-Analysis

By MedXY 10/09/2025

This meta-analysis reveals that short-term mortality in severe alcohol-associated hepatitis remains high, with no significant improvement over the past four decades despite advances in care, underscoring the urgent need for better therapies and prognostic strategies.

Gastroenterology Internal Medicine news

Obeticholic Acid Non-Response Signals Higher Clinical Risk in Primary Biliary Cholangitis

By MedXY 10/09/2025

In primary biliary cholangitis (PBC) patients treated with obeticholic acid (OCA), biochemical non-response strongly predicts a higher risk of clinical events including liver decompensation and mortality, underscoring the need for improved therapies.

Gastroenterology Internal Medicine news

Gut Microbiota Dysbiosis in Cirrhotic Portal Hypertension: Unraveling Microbial Contributions to Disease Progression

By MedXY 10/09/2025

Altered gut microbiota composition and metabolism exacerbate cirrhotic portal hypertension, highlighting potential microbiome-targeted therapies to mitigate disease progression.

Internal Medicine Neurology news

Aspirin Use in Older Adults: Insights from the ASPREE-XT Study on Healthy Lifespan

By MedXY 10/07/2025

Extended follow-up from the ASPREE-XT study shows low-dose aspirin does not improve healthy lifespan—defined as survival free of dementia, persistent disability, or death—in healthy older adults, and its risks include increased major hemorrhagic events.

Allergy & Immunology Internal Medicine news

Guardians Within: The Nobel-Winning Discovery of Regulatory T Cells and Their Role in Immune Balance

By MedXY 10/06/2025

The 2025 Nobel Prize in Physiology or Medicine honors groundbreaking work on regulatory T cells, revealing how the immune system avoids self-attack while combating threats, paving the way for novel therapies in autoimmune and transplant medicine.

Internal Medicine news Public Health

Support for Alcohol Control Policies Among US Alcohol Consumers

By MedXY 10/04/2025

Many US adults who consume alcohol support policies like cancer warnings and advertising restrictions on alcohol, with demographic variations in support levels.

Internal Medicine news Respiratory

Evaluating Hypertonic Saline and Carbocisteine in Non-Cystic Fibrosis Bronchiectasis: Insights from the CLEAR Trial

By MedXY 10/04/2025

This article reviews a robust UK trial assessing hypertonic saline and carbocisteine in bronchiectasis, revealing no significant reduction in pulmonary exacerbations over 52 weeks, highlighting the need for continued research on mucoactive therapies.

Cardiology Internal Medicine

Optimizing Extended Apixaban Therapy for Venous Thromboembolism: Insights from Recent Randomized Trials

By MedXY 09/26/2025

Extended low-dose apixaban significantly reduces recurrent venous thromboembolism (VTE) in patients with provoked VTE and enduring risk factors, with minimal major bleeding. Reduced-dose apixaban for cancer-associated VTE is equally effective as full dose but lowers bleeding risk.

Cardiology Clinical Updates Internal Medicine news

Extended Apixaban Therapy Reduces Recurrent VTE Risk in Patients with Provoked Events and Enduring Risk Factors

By MedXY 09/26/2025

A randomized trial demonstrates that low-dose apixaban for 12 months significantly lowers symptomatic recurrent VTE risk after provoked events with enduring risk factors, with minimal major bleeding.

Family Medicine & Nutrition Internal Medicine news Specialties

Challenges and Insights in Sustaining Weight Loss: Evaluating Adaptive vs Static Support

By MedXY 09/23/2025

A recent trial comparing adaptive, algorithm-driven telephone support with static monthly coaching found no significant difference in long-term weight loss maintenance, highlighting complexities in obesity treatment and the need for refined, patient-centered interventions.

Family Medicine & Nutrition Internal Medicine news Specialties

The Hidden Purines in Plant-Based Diets: What High Uric Acid Patients Need to Know

By MedXY 09/21/2025

High uric acid is linked to several diseases, and many avoid meat fearing purines. However, some vegetarian foods are high in purines too. Understanding these can help better manage uric acid levels and prevent complications like gout.

Clinical Updates Diabetes & Endocrinology Internal Medicine news Specialties

Rapirosiran: A Promising RNA Interference Therapy Targeting HSD17B13 for Metabolic Dysfunction-Associated Steatohepatitis

By MedXY 09/20/2025

This phase I randomized study shows rapirosiran, an RNAi therapeutic targeting HSD17B13, is safe and effectively reduces liver HSD17B13 mRNA in patients with metabolic dysfunction-associated steatohepatitis (MASH).

AI Clinical Updates Gastroenterology Internal Medicine news Pathology & Lab Medicine

Enhancing Fibrosis Scoring in MASH: The Role of AI-Enhanced Digital Pathology

By MedXY 09/20/2025

AI-assisted digital pathology improves inter-pathologist agreement on fibrosis staging in metabolic dysfunction-associated steatohepatitis (MASH), enhancing clinical trial accuracy and efficiency.

Clinical Updates Gastroenterology Internal Medicine news Specialties

HEC88473 Dual GLP-1/FGF21 Agonist: Advancing Treatment for MASLD and T2DM with Promising Safety and Efficacy

By MedXY 09/20/2025

A phase Ib/IIa trial demonstrated that HEC88473, a novel GLP-1/FGF21 dual agonist, is generally safe, effectively reduces liver fat, and improves glycemic and lipid profiles in MASLD patients with type 2 diabetes within five weeks of treatment.

Clinical Updates Gastroenterology Internal Medicine news

AZD2693: Targeting PNPLA3 148M Variant as a Precision Therapy for Metabolic Steatohepatitis

By MedXY 09/20/2025

AZD2693, a liver-directed antisense oligonucleotide, safely reduces PNPLA3 expression and liver fat in homozygous PNPLA3 148M carriers with metabolic dysfunction-associated steatohepatitis, signaling promise for precision treatment in this genetically defined subgroup.

Clinical Updates Gastroenterology Internal Medicine news

Rapirosiran: A Promising RNAi Therapy Targeting HSD17B13 in Metabolic Dysfunction-Associated Steatohepatitis

By MedXY 09/20/2025

This phase I study evaluates rapirosiran, an RNA interference therapeutic targeting HSD17B13, demonstrating safety, tolerability, and significant liver mRNA reduction in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Clinical Updates Gastroenterology Internal Medicine news Specialties

Pan-PPAR Agonist Lanifibranor: A Breakthrough in Improving Insulin Resistance and Hepatic Steatosis in T2D and MASLD Patients

By MedXY 09/20/2025

Lanifibranor, a pan-PPAR agonist, significantly reduces liver fat and improves insulin sensitivity at multiple tissue sites in type 2 diabetes patients with MASLD, offering a new therapeutic avenue to address underlying metabolic dysfunction.

Clinical Updates Gastroenterology Internal Medicine news

Icosabutate in Metabolic Dysfunction-Associated Steatohepatitis: Insights from the Phase IIb ICONA Trial

By MedXY 09/20/2025

A phase IIb trial of the FFAR1/FFAR4 agonist icosabutate in MASH shows encouraging fibrosis improvement and biomarker responses despite not meeting the primary endpoint, supporting further development.